The estimated Net Worth of Robert Petit is at least $264 Tisíc dollars as of 5 November 2018. Robert Petit owns over 3,963 units of Ayala Pharmaceuticals stock worth over $4,624 and over the last 11 years Robert sold ADXS stock worth over $259,841.
Sign up
Robert Petit ADXS stock SEC Form 4 insiders trading
Robert has made over 13 trades of the Ayala Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Robert sold 3,963 units of ADXS stock worth $2,299 on 5 November 2018.
The largest trade Robert's ever made was buying 12,800 units of Ayala Pharmaceuticals stock on 24 October 2013 worth over $51,200. On average, Robert trades about 956 units every 27 days since 2013. As of 5 November 2018 Robert still owns at least 231,206 units of Ayala Pharmaceuticals stock.
You can see the complete history of Robert Petit stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Petit's mailing address?
Robert's mailing address filed with the SEC is 305 COLLEGE ROAD EAST, , PRINCETON, NJ, 08540.
Insiders trading at Ayala Pharmaceuticals
Over the last 21 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C.... a Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.
What does Ayala Pharmaceuticals do?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
What does Ayala Pharmaceuticals's logo look like?
Complete history of Robert Petit stock trades at Ayala Pharmaceuticals
Ayala Pharmaceuticals executives and stock owners
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Kenneth A. Berlin J.D.,
Pres, Interim CFO, CEO & Director -
Kenneth Berlin,
President, Chief Executive Officer, Interim Chief Financial Officer, Director -
Andres Gutierrez,
Chief Medical Officer and Executive Vice President -
Dr. Andres A. Gutierrez M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Roni Appel,
Independent Director -
David Sidransky,
Independent Chairman of the Board -
James Patton,
Independent Non-Executive Vice Chairman of the Board -
Tim McCarthy,
Investor Relations -
Samir Khleif,
Independent Director -
Richard Berman,
Independent Director -
Igor Gitelman CPA, CPA, M.B.A., MBA,
Chief Accounting Officer & VP of Fin. -
Gregory T. Mayes,,
Chief Operating Officer -
Robert J. Spiegel,
Director -
Robert Petit,
Chief Scientific Officer -
Sara Bonstein,
Chief Financial Officer -
Thomas J Mckearn,
Director -
Thomas J Ridge,
Director -
Murray A Goldberg,
Director -
Biotech Fund I, L.P.Israel ...,
-
Capital Partners Gp, L.L.C....,
-
Anthony A Lombardo,
Interim CEO -
Molly Henderson,
Executive Vice President & CFO -
Fredrick D Cobb,
Vice President Finance -
John F Rothman,
VP of Clinical Development -
David J Mauro,
Chief Medical Officer -
Daniel J. O'connor,
SVP, Legal & Business Dev Off -
Thomas A Moore,
Director -
Christy Lee French,
Exec. Dir. of Medical Affairs -
Mark J Rosenblum,
Chief Financial Officer -
Biotech Fund I, L.P.Israel ...,
-
Growth Fund Limited Partner...,
10% owner -
Vered Bisker Leib,
Director